Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

Background Among patients with resectable early-stage non–small-cell lung cancer
(NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune …

Background Amivantamab has been approved for the treatment of patients with advanced
non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 …

Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

Single-cell technologies have revealed the complexity of the tumour immune
microenvironment with unparalleled resolution,,,,,,,–. Most clinical strategies rely on …

Background VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite
high initial response rates, almost all patients eventually develop treatment resistance to …

KEYNOTE-042 is a randomized phase III study that showed significantly longer overall
survival (OS) with pembrolizumab monotherapy versus platinum-based chemotherapy in …

Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer
(NSCLC) often develop resistance to current standard third-generation EGFR tyrosine …